GeneProt expands proteomic capabilities

Swiss industrial-scale proteomic company GeneProt has amended its scientific collaboration with Novartis Pharma to maximise the value from the synergy of GeneProt's industrial-scale approach to proteomics and Novartis' high-throughput biological validation platforms.

In October 2000, GeneProt and Novartis entered into a four-year collaboration to perform large-scale proteomic studies for different therapeutic areas. Under the new collaboration agreement, GeneProt will continue to use its large-scale proteomics platform and will accelerate the delivery of proteins to Novartis for further biological evaluation. GeneProt will also take advantage of the new platforms it has developed to perform innovative proteomics such as accelerated studies on non-pooled samples, or pharmacoproteomics.

GeneProt is focused on separating, identifying, characterising, selecting and synthesising human proteins on behalf of life sciences companies and for its own account for use in the discovery and development of new therapeutic proteins, protein drug targets and protein biomarkers. It analyses polypeptides and smaller proteins using its MicroProt process at its industrial-scale proteomics facility in Geneva.